Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 5/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17580070 | 0.81 | PLK1 (0.37) | HDAC2HDAC8HDAC6HPGDTSHR | |
| SCHEMBL23511758 | 0.78 | HDAC6 (0.41) | P2RX7HDAC2HDAC8HDAC6 | |
| SCHEMBL2363536 | 0.78 | P2RX7 (0.60) | P2RX7HDAC2HDAC8HDAC6HTT | |
| SCHEMBL6221739 | 0.76 | P2RX7 (0.64) | P2RX7HTTSMN1; SMN2GAA | |
| SCHEMBL6382380 | 0.76 | P2RX7 (0.38) | P2RX7HDAC6HPGDHTTCYP46A1 | |
| SCHEMBL11036636 | 0.76 | P2RX7 (0.33) | P2RX7 | |
| SCHEMBL12179242 | 0.74 | CNR1 (0.42) | P2RX7HDAC2HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL12471584 | 0.74 | HDAC6 (0.35) | P2RX7HDAC2HDAC8HDAC6HPGD | |
| SCHEMBL14903866 | 0.73 | PTK2 (0.40) | TSHRSMN1; SMN2BAZ2BGAA | |
| SCHEMBL24655828 | 0.73 | P2RX7 (0.39) | P2RX7HDAC2HDAC8HDAC6PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074786-B | Process for preparing triazine carbamates | 湛新荷兰有限公司 | 2020-09-22 | — | — | CN | disclosed |
| EP-3191460-B1 | PROCESS FOR THE PREPARATION OF TRIAZINE CARBAMATES | ALLNEX NETHERLANDS BV (NL) | 2020-01-29 | — | — | EP | disclosed |
| CN-105026377-B | Process for preparing triazine carbamates | 湛新荷兰有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-10071972-B2 | Process for the preparation of triazine carbamates | ALLNEX NETHERLANDS B.V. (NL) | 2018-09-11 | — | — | US | disclosed |
| US-20170233353-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE CARBAMATES | ALLNEX IP S.À.R.L. (LU) | 2017-08-17 | — | — | US | disclosed |
| EP-3191460-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE CARBAMATES | Allnex IP S.à.r.l. (LU) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016037973-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE CARBAMATES | ALLNEX IP S.À.R.L. (LU) | 2016-03-17 | — | — | WO | disclosed |
| EP-2995613-A1 | Process for the preparation of triazine carbamates | Allnex IP S.à.r.l. (LU) | 2016-03-16 | — | — | EP | disclosed |
| EP-2964619-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE CARBAMATES | Allnex IP S.à.r.l. (LU) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014135463-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE CARBAMATES | ALLNEX IP S.À.R.L. (LU) | 2014-09-12 | — | — | WO | disclosed |
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | MTOR, PIKFYVE, RICTOR | P2RX7 4052/4885HDAC2 328/4885HDAC8 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.